Tags

Type your tag names separated by a space and hit enter

Control of T cell activation by CD4+CD25+ suppressor T cells.
Novartis Found Symp 2003; 252:24-36; discussion 36-44, 106-14NF

Abstract

Although the concept of a separate lineage of T cells specifically equipped to suppress immune responses was initially proposed more than 30 years ago, progress in this area of immunoregulation has been hampered by the lack of solid biochemical and molecular data to support the existence of the soluble products of these purported suppressor T cells. Studies over the past 5-10 years have identified a distinct lineage of CD4+CD25+ regulatory or suppressor T cells that control autoreactive effector cells and prevent autoimmunity. The mechanism by which CD4+CD25+ T cells inhibit T cell activation in vivo or in vitro is still poorly defined. While autoreactive effector T cells undergo massive proliferation and expansion following injection into immunocompromised recipients, CD4+CD25+ T cells do not inhibit this lymphopaenia-induced proliferation and act later in the activation process at the site of immune damage in the target organ. The development of in vitro models that partially mimic the in vivo properties of the CD4+CD25+ regulatory T cells has facilitated their characterization. A member of the tumour necrosis receptor family, the GITR is expressed on CD4+CD25+ T cells and after interaction with its ligand down-regulates suppressor activity. Multiple methods of manipulating both the numbers of CD4+CD25+ suppressor T cells and their activation status are now available and will rapidly be applied to therapy of autoimmune, infectious and malignant diseases.

Authors+Show Affiliations

Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1892, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14609210

Citation

Shevach, Ethan M., et al. "Control of T Cell Activation By CD4+CD25+ Suppressor T Cells." Novartis Foundation Symposium, vol. 252, 2003, pp. 24-36; discussion 36-44, 106-14.
Shevach EM, Piccirillo CA, Thornton AM, et al. Control of T cell activation by CD4+CD25+ suppressor T cells. Novartis Found Symp. 2003;252:24-36; discussion 36-44, 106-14.
Shevach, E. M., Piccirillo, C. A., Thornton, A. M., & McHugh, R. S. (2003). Control of T cell activation by CD4+CD25+ suppressor T cells. Novartis Foundation Symposium, 252, pp. 24-36; discussion 36-44, 106-14.
Shevach EM, et al. Control of T Cell Activation By CD4+CD25+ Suppressor T Cells. Novartis Found Symp. 2003;252:24-36; discussion 36-44, 106-14. PubMed PMID: 14609210.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Control of T cell activation by CD4+CD25+ suppressor T cells. AU - Shevach,Ethan M, AU - Piccirillo,Ciriaco A, AU - Thornton,Angela M, AU - McHugh,Rebecca S, PY - 2003/11/12/pubmed PY - 2004/4/9/medline PY - 2003/11/12/entrez SP - 24-36; discussion 36-44, 106-14 JF - Novartis Foundation symposium JO - Novartis Found. Symp. VL - 252 N2 - Although the concept of a separate lineage of T cells specifically equipped to suppress immune responses was initially proposed more than 30 years ago, progress in this area of immunoregulation has been hampered by the lack of solid biochemical and molecular data to support the existence of the soluble products of these purported suppressor T cells. Studies over the past 5-10 years have identified a distinct lineage of CD4+CD25+ regulatory or suppressor T cells that control autoreactive effector cells and prevent autoimmunity. The mechanism by which CD4+CD25+ T cells inhibit T cell activation in vivo or in vitro is still poorly defined. While autoreactive effector T cells undergo massive proliferation and expansion following injection into immunocompromised recipients, CD4+CD25+ T cells do not inhibit this lymphopaenia-induced proliferation and act later in the activation process at the site of immune damage in the target organ. The development of in vitro models that partially mimic the in vivo properties of the CD4+CD25+ regulatory T cells has facilitated their characterization. A member of the tumour necrosis receptor family, the GITR is expressed on CD4+CD25+ T cells and after interaction with its ligand down-regulates suppressor activity. Multiple methods of manipulating both the numbers of CD4+CD25+ suppressor T cells and their activation status are now available and will rapidly be applied to therapy of autoimmune, infectious and malignant diseases. SN - 1528-2511 UR - https://www.unboundmedicine.com/medline/citation/14609210/Control_of_T_cell_activation_by_CD4+CD25+_suppressor_T_cells_ DB - PRIME DP - Unbound Medicine ER -